Masanori Fukazawa

Gotenba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: November 12, 2020

Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys.

Pharmacological analysis of SGLT2 inhibitor (tofogliflozin) using in vivo glucose clamp and titration protocols in rats and cynomolgus monkeys.

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: November 03, 2016

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.

Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice.

Journal: Endocrinology

Published: December 30, 2015

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.

Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.

Journal: Journal of diabetes research

Published: June 16, 2015

Relationship between the brain natriuretic peptide (BNP) level and remission of diabetic nephropathy with microalbuminuria: a 3-year follow-up study.

Relationship between the brain natriuretic peptide (BNP) level and remission of diabetic nephropathy with microalbuminuria: a 3-year follow-up study.

Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

Published: November 20, 2014

Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.

Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.

Journal: American journal of physiology. Renal physiology

Published: April 25, 2014

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.

Journal: Nutrition & diabetes

Published: March 19, 2014

Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.

Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.

Journal: Diabetes, obesity & metabolism

Published: August 06, 2013

Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.

Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.

Journal: British journal of pharmacology

Published: February 08, 2013

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Journal: American journal of physiology. Endocrinology and metabolism

Published: December 20, 2012

SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose.

SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose.

Journal: PloS one

Published: October 19, 2012

Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.

Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.

Journal: The Journal of pharmacology and experimental therapeutics

Published: March 14, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026